CD8A and neoplasm: ARG1 inhibitors (such as CB-1158) showed encouraging preclinical results (346), increasing tumor-infiltrating NK cells and CD8+ T cells (345, 347), reducing tumor burden (348, 349), and decreasing MDSCs recruitment into the TME (345).